{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:41:21Z","timestamp":1740120081617,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Recombinant porcine factor VIII (rpFVIII) is a hemostatic agent for acquired hemophilia A (AHA). Cross-reaction of auto-antibodies against rpFVIII has been reported, although no data are available in Japanese patients. This study investigated the cross-reactivity and coagulation potential of rpFVIII in plasma samples from Japanese patients with AHA. Cross-reactivity was calculated as the ratio of anti-porcine FVIII inhibitor titer (pFVIII-INH) to human FVIII inhibitor titer. Comprehensive coagulation potential was assessed by clot waveform analysis (CWA) and thrombin generation assay (TGA) in samples spiked with rpFVIII (equivalent to 200 U\/kg). Nine of 16 plasma samples (56.3%) had positive pFVIII-INH, with a median cross-reactivity of 1.2%. FVIII activity (FVIII:C) was restored to\u2009&gt;\u2009100% in all samples upon spiking with rpFVIII, but was weakly correlated with pFVIII-INH. CWA parameters and most TGA parameters were restored to normal upon spiking with rpFVIII; correlation of these parameters with FVIII:C was similar to that observed in controls. Overall, cross-reactivity to rpFVIII in Japanese patients was similar to that reported in Caucasian patients. Our results suggest that an initial clinical dose of 200 U\/kg rpFVIII could restore coagulation potential to normal, and that FVIII:C monitoring after rpFVIII administration may be more informative than pFVIII-INH before administration.<\/jats:p>","DOI":"10.1007\/s12185-024-03854-5","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:17:10Z","timestamp":1730305030000},"page":"45-55","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The in vitro cross-reactivity and blood coagulation potential of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A"],"prefix":"10.1007","volume":"121","author":[{"given":"Masahiro","family":"Takeyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Sasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Miyaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruto","family":"Shimonishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2415-2194","authenticated-orcid":false,"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"3854_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0950-3536(96)80067-9","volume":"9","author":"AJ Cohen","year":"1996","unstructured":"Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol. 1996;9:33\u2013154.","journal-title":"Baillieres Clin Haematol"},{"key":"3854_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0950-3536(98)80049-8","volume":"11","author":"CR Hay","year":"1998","unstructured":"Hay CR. Acquired haemophilia. Baillieres Clin Haematol. 1998;11:287\u2013303.","journal-title":"Baillieres Clin Haematol"},{"key":"3854_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2491\/jjsth.28.715","volume":"28","author":"M Sakai","year":"2017","unstructured":"Sakai M, Amano K, Ogawa K, Takami A, Tokugawa T, Nogami K, et al. Guidelines for the management of acquired hemophilia A: 2017 revision. Jpn J Thromb Hemost. 2017;28:715\u201347.","journal-title":"Jpn J Thromb Hemost"},{"key":"3854_CR4","unstructured":"Hemlibra [package insert]. Japan: Chugai; 2022. https:\/\/www.info.pmda.go.jp\/go\/pack\/6343451A1025_1_06\/. Accessed 31 Jan 2024."},{"key":"3854_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2516.2012.02803.x","volume":"18","author":"PL Giangrande","year":"2012","unstructured":"Giangrande PL. Porcine factor VIII. Haemophilia. 2012;18:305\u20139.","journal-title":"Haemophilia"},{"key":"3854_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.V71.1.137.137","volume":"71","author":"P Lollar","year":"1988","unstructured":"Lollar P, Parker CG, Tracy RP. Molecular characterization of commercial porcine factor VIII concentrate. Blood. 1988;71:137\u201343.","journal-title":"Blood"},{"key":"3854_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1046\/j.1537-2995.2000.40060708.x","volume":"40","author":"JM Soucie","year":"2000","unstructured":"Soucie JM, Erdman DD, Evatt BL, Anderson LJ, T\u00f6r\u00f6k TJ, El-Jamil M, et al. Investigation of porcine parvovirus among persons with hemophilia receiving Hyate: C porcine factor VIII concentrate. Transfusion. 2000;40:708\u201311.","journal-title":"Transfusion"},{"key":"3854_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2491\/jjsth.2.487","volume":"2","author":"H Fukui","year":"1991","unstructured":"Fukui H, Yoshioka A, Shima M, Mori K, Yorifuji H, Kinoshita T, et al. Multicenter clinical study of a highly purified porcine factor VIII concentrate [MTI-9002 (Hyate: C)] in hemophilia A patients with inhibitor. Jpn J Thromb Hemost. 1991;2:487\u2013500.","journal-title":"Jpn J Thromb Hemost"},{"key":"3854_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/hae.12784","volume":"22","author":"D Lillicrap","year":"2016","unstructured":"Lillicrap D, Schiviz A, Apostol C, Wojciechowski P, Horling F, Lai CK, et al. Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile. Haemophilia. 2016;22:308\u201317.","journal-title":"Haemophilia"},{"key":"3854_CR10","doi-asserted-by":"crossref","unstructured":"Seki Y, Ogawa Y, Kikuchi T, Sakaida E, Mizuta Y, Kitagawa T, et al. Efficacy and safety of recombinant porcine factor VIII in Japanese patients with acquired hemophilia A. Int J Hematol. 2024;120:482\u201391.","DOI":"10.1007\/s12185-024-03823-y"},{"key":"3854_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/hae.12627","volume":"21","author":"R Kruse-Jarres","year":"2015","unstructured":"Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, et al. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015;21:162\u201370.","journal-title":"Haemophilia"},{"key":"3854_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jth.14618","volume":"18","author":"H T\u00fcrkantoz","year":"2020","unstructured":"T\u00fcrkantoz H, K\u00f6nigs C, Kn\u00f6bl P, Klamroth R, Holstein K, Huth-K\u00fchne A, et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: data from the GTH-AH 01\/2010 Study. J Thromb Haemost. 2020;18:36\u201343.","journal-title":"J Thromb Haemost"},{"key":"3854_CR13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/jth.12987","volume":"13","author":"S Furukawa","year":"2015","unstructured":"Furukawa S, Nogami K, Ogiwara K, Yada K, Minami H, Shima M. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. J Thromb Haemost. 2015;13:1279\u201384.","journal-title":"J Thromb Haemost"},{"key":"3854_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/bjh.16574","volume":"190","author":"S Furukawa","year":"2020","unstructured":"Furukawa S, Nogami K, Shimonishi N, Nakajima Y, Matsumoto T, Shima M. Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors. Br J Haematol. 2020;190:727\u201335.","journal-title":"Br J Haematol"},{"key":"3854_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jth.12488","volume":"12","author":"J Haku","year":"2014","unstructured":"Haku J, Nogami K, Matsumoto T, Ogiwara K, Shima M. Optimal monitoring of bypass therapy in hemophilia A patients with inhibitors by the use of clot waveform analysis. J Thromb Haemost. 2014;12:355\u201362.","journal-title":"J Thromb Haemost"},{"key":"3854_CR16","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12185-020-02959-x","volume":"112","author":"K Ogiwara","year":"2020","unstructured":"Ogiwara K, Nogami K, Matsumoto N, Noguchi-Sasaki M, Hirata M, Soeda T, et al. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa\/X. Int J Hematol. 2020;112:621\u201330.","journal-title":"Int J Hematol"},{"key":"3854_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12731","volume":"6","author":"C N\u00e9grier","year":"2022","unstructured":"N\u00e9grier C, Oldenburg J, Kenet G, Meeks SL, Bordet JC, M\u00fcller J, et al. Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors. Res Pract Thromb Haemost. 2022;6: e12731.","journal-title":"Res Pract Thromb Haemost"},{"key":"3854_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2257.2004.00605.x","volume":"26","author":"M Okuda","year":"2004","unstructured":"Okuda M, Yamamoto Y. Usefulness of synthetic phospholipid in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clin Lab Haematol. 2004;26:215\u201323.","journal-title":"Clin Lab Haematol"},{"key":"3854_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1160\/TH11-05-0331","volume":"107","author":"T Matsumoto","year":"2012","unstructured":"Matsumoto T, Nogami K, Ogiwara K, Shima M. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired haemophilia A patients with anti-C2 autoantibodies. Thromb Haemost. 2012;107:288\u2013301.","journal-title":"Thromb Haemost"},{"key":"3854_CR20","first-page":"612","volume":"34","author":"CK Kasper","year":"1975","unstructured":"Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:612.","journal-title":"Thromb Diath Haemorrh"},{"key":"3854_CR21","doi-asserted-by":"publisher","first-page":"e427","DOI":"10.1111\/hae.13266","volume":"23","author":"T Matsumoto","year":"2017","unstructured":"Matsumoto T, Nogami K, Tabuchi Y, Yada K, Ogiwara K, Kurono H, et al. Clot waveform analysis using CS-2000i\u2122 distinguishes between very low and absent levels of factor VIII activity in patients with severe haemophilia A. Haemophilia. 2017;23:e427\u201335.","journal-title":"Haemophilia"},{"key":"3854_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/jth.14022","volume":"16","author":"K Nogami","year":"2018","unstructured":"Nogami K, Matsumoto T, Tabuchi Y, Soeda T, Arai N, Kitazawa T, et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab. J Thromb Haemost. 2018;16:1078\u201388.","journal-title":"J Thromb Haemost"},{"key":"3854_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000071636","volume":"33","author":"HC Hemker","year":"2003","unstructured":"Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4\u201315.","journal-title":"Pathophysiol Haemost Thromb"},{"key":"3854_CR24","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s12185-009-0450-y","volume":"90","author":"T Matsumoto","year":"2009","unstructured":"Matsumoto T, Nogami K, Ogiwara K, Shima M. A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A. Int J Hematol. 2009;90:576\u201382.","journal-title":"Int J Hematol"},{"key":"3854_CR25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2491\/jjsth.24.640","volume":"24","author":"M Sakai","year":"2013","unstructured":"Sakai M, Taki M, Ieko M, Ida K, Ohira K, Katsunuma T, et al. 2013 revised edition: hemostatic treatment guidelines for inhibitors possess congenital hemophilia patients. Jpn J Thromb Hemost. 2013;24:640\u201358.","journal-title":"Jpn J Thromb Hemost."},{"key":"3854_CR26","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1182\/blood.V89.10.3663","volume":"89","author":"R Prescott","year":"1997","unstructured":"Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood. 1997;89:3663\u201371.","journal-title":"Blood"},{"key":"3854_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0022-2143(99)90082-3","volume":"133","author":"D Green","year":"1999","unstructured":"Green D, Blanc J, Foiles N. Spontaneous inhibitors of factor VIII: Kinetics of inactivation of human and porcine factor VIII. J Lab Clin Med. 1999;133:260\u20134.","journal-title":"J Lab Clin Med"},{"key":"3854_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12185-021-03249-w","volume":"155","author":"M Takeyama","year":"2022","unstructured":"Takeyama M, Sasai K, Matsumoto T, Furukawa S, Ogiwara K, Yada K, et al. Comprehensive blood coagulation potential in patients with acquired hemophilia A: retrospective analyses of plasma samples obtained from nationwide centers across Japan. Int J Hematol. 2022;115:163\u201372.","journal-title":"Int J Hematol"},{"key":"3854_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12185-021-03249-w","volume":"115","author":"M Takeyama","year":"2022","unstructured":"Khayat C, Marchi R, Durual S, Lecompte T, Neerman-Arbez M, Casini A. Impact of fibrinogen infusion on thrombin generation and fibrin clot structure in patients with inherited afibrinogenemia. Thromb Haemost. 2022;122:1461\u20138.","journal-title":"Int J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03854-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T15:51:56Z","timestamp":1737215516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03854-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3854"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03854-5","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2024,10,30]]},"assertion":[{"value":"9 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"YM and HU are employees of Takeda Pharmaceutical Co., Ltd (Takeda). NS taught a course endowed by CSL Behring. YN has received a grant from Takeda. KN has received research grants from Bayer, Chugai Pharmaceutical, CSL, Fujimoto Pharmaceutical Corp, KM Biologics, Novo Nordisk, Sanofi, Sekisui, Sysmex, and Takeda; and honoraria from Bayer, Chugai Pharmaceutical, CSL, Fujimoto Pharmaceutical Corp, KM Biologics, Novo Nordisk, Sanofi, Sekisui, Sysmex, and Takeda. KO, KS, MT and SF have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}